Search
At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talks the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more
He described the discovery work that Alloy does with its client partners, and highlighted emerging areas of science. Plus, the importance...
39 minutes ago
At the recent Timmerman Report west coast anniversary celebration, HSBC Innovation Banking's Jesse Essaff discussed Seattle's venture environment and how HSBC helps entrepreneurs
A director at HSBC Innovation Banking for biopharma, diagnostics, and tools, he shares the data on the current environment both for...
3 hours ago
Oxford, UK based Greywolf Therapeutics is pursuing cancer and autoimmune indications by attempting to target T-cells at their first signal of activation - an approach the company leads the field on
Co-Founder and CEO Peter Joyce describes the science behind this, including how the company's lead programs inhibit Endoplasmic Reticulum...
4 hours ago
BioVenture VoiCes Episode 15: Mission BioCapital's Steve Tregay
Steve Tregay describes his career path, including how early roles at Array BioPharma and Novartis led him to found Forma Therapeutics. He...
2 days ago
Brainomix, an Oxford, UK based company that uses AI to help front line physicians analyze CT scans for stroke damage and interstitial lung disease, announced an $18M series C raise today
Co-Founder and CEO Michalis Papadakis describes the unmet need for a quick, accurate assessment of stroke damage by front line...
6 days ago
AnaptysBio's CEO discusses recent 12 week RA data from the company's PD-1 depleter and agonist, rosnilimab, and previews other upcoming catalysts
Daniel Faga goes over the recently released rosnilimab RA data and previews a longer-term follow-up that will be out in the second...
7 days ago
Analyst Tuesdays: Mizuho Senior Analyst Graig Suvannavejh shares his take on the difficult biotech environment and discusses upcoming clinical trail catalysts for companies he covers
He sets the table for upcoming readouts from Axsome, Vigil Neuro, Verastem, Corvus, and Harmony Biosciences.
Mar 18
The co-founders of Vevo Therapeutics describe the Arc Virtual Cell Atlas, a large single cell atlas made publicly available with Arc Institute that now includes Vevo's Tahoe-100M database
CEO Nima Alidoust and CSO Johnny Yu describe Vevo's contribution of 100M cells, plus a 60,000 drug-patient interaction map, that has been...
Mar 17
Biotech CEO Sisterhood: Alnylam CEO Yvonne Greenstreet on her career path, the importance of diversity of opinions, and leading Alnlyam into a critical phase of growth
Interviewed by Sisterhood editorial board member Sheila Gujrathi, Yvonne Greenstreet describes her upbringing and early career as a...
Mar 17
Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target
Founder & CEO John Mulligan describes how he and his team sold an asset using the same science to Roche in 2022 for $250 million when...
Mar 14
From struggling with sickle cell disease to climbing mountains - a firsthand account of how gene therapy has been life changing
Jimi Olaghere describes how his life has changed after participating in a clinical trial for the CRISPR based gene therapy for sickle...
Mar 14
Alta Partners' Managing Director Bob More shares his take on biotech and his philosophy of investing in people - from the Timmerman Report 10th Anniversary Celebration in Seattle
He discusses the current downturn, they key of being focused, and his preference of investing in people first. Plus, comments on...
Mar 13
Congratulations to Luke Timmerman on 10 years of Timmerman Report. We salute you!
Celebrating with the Seattle (and beyond) biotech community.
Mar 13
Tour of Scotland: Glasgow based EnteroBiotix is developing microbiome based treatments using a 'full ecosystem' of strains you would expect to see in a healthy microbiome
CEO James McIlroy describes the scientific platform and how it contrasts to other microbiome approaches. A trial in IBS is scheduled to...
Mar 13
Tour of Scotland: Scotland's Chief Scientist (Health) describes how new technologies are being embraced in the NHS, and why Scotland is a good place for global companies to run clinical trials
Professor Dame Anna Dominiczak describes how new technologies are being rolled out in the community equitably, such as digital...
Mar 13
HumanX: Generate Biomedicines' CEO Mike Nally describes how he sees AI going from improvements in optimization to drugging the undruggable
From the big HumanX AI conference in Las Vegas, he describes the overall path he sees AI taking in its contributions to drug development,...
Mar 13
Tour of Scotland: St. Andrews based Pneumagen aims to prevent viral respiratory infections with an intra-nasally delivered platform that harnesses glycan targeted Carbohydrate Binding Module domains
Co-Founder & CEO Douglas Thomson describes how the company was founded, and walks us through the science. Plus, a recap of recently...
Mar 13
Tour of Scotland: Dundee based Glen Clova Scientific is using virus-like particles to lower levels of cytokines in patients experiencing chronic inflammatory conditions
CEO Steven Powell joins BiotechTV from Scotland's Life Sciences Conference and Awards in Glasgow, and explains Glen Clova's expertise in...
Mar 13
Tour of Scotland: Mark Cook, Co-Chair of Life Sciences Scotland, describes the importance of life sciences to the area and what the government and industry are doing to support it
He describes the assets that Scotland has to offer the industry such as excellent universities that derive innovation and a diverse...
Mar 13
Tour of Scotland: Glasgow based Mironid is developing a small molecule to directly target aberrantly high cAMP that causes Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Co-Founder & CEO Neil Wilkie walks us through the biology of ADPKD and explains how Mironid is trying to uniquely directly target it....
Mar 13
.png){kind=logo}
